Far Infrared Sauna Therapy for Cardiovascular Health

Cardiovascular disease remains the leading cause of death worldwide, responsible for approximately one in three deaths globally. While pharmaceutical and surgical interventions have advanced significantly, a growing body of peer-reviewed evidence demonstrates that far infrared sauna therapy produces measurable, clinically meaningful improvements in cardiac function, vascular endothelial health, and blood pressure regulation.

This is not a fringe claim. The cardiovascular evidence for far infrared therapy is the deepest and most rigorous of any clinical application of FIR. The research program spans more than two decades, originates primarily from Kagoshima University in Japan under the direction of cardiologist Chuwa Tei, and has been published in journals including the Journal of the American College of Cardiology, Circulation Journal, and the Journal of the American Society of Nephrology. It includes multicenter prospective randomized controlled trials—the gold standard of clinical evidence.

This page reviews that evidence condition by condition so you can evaluate FIR cardiovascular therapy with the rigor it deserves.

How Far Infrared Radiation Supports Cardiovascular Function

Endothelial Nitric Oxide Synthase Upregulation

The endothelium—the single-cell lining of every blood vessel—is the master regulator of vascular tone, and its primary signaling molecule is nitric oxide. Endothelial dysfunction—reduced nitric oxide bioavailability—is recognized as one of the earliest and most important pathological events in cardiovascular disease, preceding and predicting atherosclerosis, hypertension, and heart failure.

Far infrared therapy directly addresses this mechanism. Ikeda and colleagues demonstrated that four weeks of FIR dry sauna therapy upregulated endothelial nitric oxide synthase (eNOS) protein expression in arterial endothelium by approximately 50 percent, with a peak 40-fold increase in eNOS mRNA at one week (Ikeda et al. 2001). In cardiomyopathic hamsters with heart failure, repeated FIR sauna therapy increased both eNOS expression and serum nitrate concentrations—a measure of systemic NO production (Ikeda et al. 2005). At the molecular level, Chen and colleagues showed that FIR increases NO production via calcium/calmodulin-dependent protein kinase II–mediated phosphorylation of eNOS at serine 1179 (Chen et al. 2013).

Vascular Remodeling and Angiogenesis

In a mouse model of hindlimb ischemia, Akasaki and colleagues showed that five weeks of daily FIR sauna therapy increased capillary density from 416 to 757 per square millimeter and significantly improved the ischemic-to-normal-side blood perfusion ratio (0.79 vs. 0.54, p < 0.001). These effects were completely abolished by the eNOS inhibitor L-NAME and were absent in eNOS-deficient mice, confirming that FIR-driven angiogenesis is eNOS-dependent (Akasaki et al. 2006). This is one of the most elegant mechanistic demonstrations in the entire FIR literature: the thermal stimulus was identical in the knockout animals, but the vascular response was eliminated, proving the biological pathway matters as much as the heat.

Autonomic and Hemodynamic Effects

Far infrared exposure reduces systemic vascular resistance, increases cardiac output without increasing myocardial oxygen demand, and shifts autonomic tone from sympathetic dominance toward parasympathetic recovery. Heart rate variability studies consistently demonstrate increased high-frequency HRV components—a marker of vagal tone—during and after FIR sauna sessions. For patients with heart failure, where sympathetic overdrive accelerates disease progression, this autonomic reset is itself a therapeutic intervention.

The Clinical Evidence: Condition by Condition

Chronic Heart Failure

The body of evidence for FIR in heart failure is exceptional by any standard in complementary cardiovascular medicine. Tei developed the Waon therapy protocol—far infrared dry sauna at 60°C for 15 minutes followed by 30 minutes of bed rest under blankets—specifically for heart failure patients who cannot tolerate the hemodynamic stress of traditional Finnish saunas.

In a prospective multicenter study of 188 patients with chronic heart failure, patients were randomized to Waon therapy (n=112) or control (n=76). After two weeks, the Waon therapy group showed significant improvements in left ventricular ejection fraction (31.6% to 34.6%, p < 0.0001), reduction in left ventricular diastolic dimension, decreased left atrial dimension, and reduced cardiothoracic ratio. Plasma brain natriuretic peptide—the primary biomarker of heart failure severity—decreased significantly in the treatment group but not in controls (Miyata et al. 2008).

A long-term follow-up study of 129 patients with NYHA Class III or IV heart failure found that Waon therapy reduced combined cardiac death and rehospitalization by 38 percent over five years. The cardiac event rate was 31.3 percent in the sauna group versus 68.7 percent in controls (Kihara et al. 2009).

The 2016 WAON-CHF multicenter prospective randomized trial—the definitive study in this area—enrolled 149 patients with advanced heart failure across multiple Japanese hospitals. Waon therapy was administered once daily for 10 days. Plasma BNP, NYHA classification, six-minute walk distance, and cardiothoracic ratio all improved significantly in the treatment group. No serious adverse events were observed (Tei et al. 2016).

Endothelial Dysfunction and Coronary Risk Factors

Imamura and colleagues conducted a study of 25 men with at least one coronary risk factor (hypercholesterolemia, hypertension, diabetes, or smoking) and 10 healthy controls. After two weeks of daily FIR sauna therapy, flow-mediated dilation—the standard measure of endothelial function—improved significantly in the risk group, approaching levels seen in healthy controls. Blood pressure also decreased significantly. The researchers attributed the improvement to increased eNOS activity and expression driven by repeated shear stress from FIR-induced vasodilation (Imamura et al. 2001).

Blood Pressure

A study of 31 hypertensive patients receiving repeated Waon therapy found that both systolic and diastolic blood pressure decreased significantly after single sessions and showed cumulative benefit with repeated treatment over five or more sessions. Systolic pressure dropped from 118.5 to 115.1 mmHg after a single session, with progressive reductions over repeated treatments (Kubozono et al. 2021). While these absolute reductions appear modest, they are consistent with the magnitude of blood pressure reduction shown to produce meaningful decreases in cardiovascular event rates at the population level.

Peripheral Arterial Disease

Peripheral arterial disease represents a direct test of FIR’s vasodilatory and angiogenic effects. Tei and colleagues treated 20 PAD patients—including 15 with bilateral limb ischemia—with ten weeks of daily Waon therapy. All patients experienced regression of rest pain. Ischemic ulcers healed in all seven affected limbs, resulting in successful limb salvage in patients who had been deemed non-candidates for surgical revascularization. Ankle-brachial index improved significantly (Tei et al. 2007). For practitioners managing PAD patients with limited surgical options, these results represent a meaningful non-invasive alternative.

Arteriovenous Fistula Patency in Hemodialysis

One of the most clinically impactful applications of FIR therapy is in maintaining arteriovenous fistula (AVF) function for hemodialysis patients. Lin and colleagues published the landmark 2007 study showing that FIR therapy improved access blood flow and unassisted patency of AVFs in hemodialysis patients (Lin et al. 2007). A subsequent open-label randomized controlled trial found that FIR therapy three times weekly for one year produced significantly higher AVF physiologic maturation rates at three months (90.0% vs. 75.8%, p = 0.04) and clinical maturation at twelve months (81.7% vs. 59.7%, p = 0.008), with one-year unassisted patency of 87.4% versus 69.8% in controls (Lin et al. 2013).

Chen and colleagues extended these findings in a 2022 randomized controlled trial of 101 patients with advanced diabetic kidney disease, showing that FIR therapy decreased AVF failure rates within 12 months (16% vs. 35.3%, p = 0.027), increased one-year unassisted patency (84% vs. 64.7%, p = 0.017), and concurrently decreased plasma asymmetric dimethylarginine—an endogenous inhibitor of nitric oxide synthase (Chen et al. 2022). The reduction in ADMA provides a direct molecular link between FIR therapy and improved endothelial NO signaling in this population.

Ventricular Arrhythmias

Kihara and colleagues also documented that repeated FIR sauna treatment reduced the frequency of ventricular arrhythmias in patients with chronic heart failure, adding another dimension to the cardiovascular benefit profile (Kihara et al. 2004). The mechanism likely involves improved myocardial perfusion, autonomic rebalancing, and reduced sympathetic activation—all of which lower the arrhythmogenic substrate.

Meta-Analysis: A systematic review and meta-analysis of sauna bath effects on heart failure, covering nine controlled studies, found that exposure to a 60°C infrared sauna for 15 minutes followed by 30 minutes of rest, five times weekly for two to four weeks, was associated with significant reductions in BNP levels and improvements in NYHA functional class. Only infrared sauna studies met inclusion criteria, and one study reported a 38 percent reduction in combined cardiac events (Källström et al. 2018).

Why Emitter Quality Matters for Cardiovascular Therapy

Every cardiovascular study cited on this page used FIR dry sauna emitters operating in the 7–14 micron range at precisely controlled temperatures. The Waon therapy protocol specifically requires consistent, high-purity FIR output at 60°C—not simply a hot enclosure with some infrared component in a mixed spectrum.

The Relax Sauna uses a patented semiconductor chip emitter that produces near 100 percent far infrared output at a peak wavelength near 9.4 microns, confirmed by bolometer testing. This delivers the spectral purity and energy density on which the Waon therapy protocol and its documented cardiovascular outcomes depend. Carbon fiber panels and ceramic rod heaters emit a broader, diluted spectrum that may not replicate the specific therapeutic stimulus used in the clinical trials.

The Relax Sauna achieves operating temperature in under 60 seconds with no preheating, produces full-body core temperature elevation of 2–3°F in 15–20 minutes, and is portable for clinical or home use. It is an FDA-registered Class II medical device.

Suggested Protocol for Cardiovascular Support

Session duration: 15 minutes at 55–60°C (131–140°F), consistent with the Waon therapy protocol used across all major cardiovascular trials.

Post-session warming: 30 minutes of bed rest under a blanket immediately after the session. This phase is a non-negotiable component of Waon therapy—it extends the period of core temperature elevation, vasodilation, and parasympathetic activation. Skipping it means you are not doing Waon therapy; you are doing something else.

Frequency: Daily sessions for 2–4 weeks during acute cardiovascular management (the Tei protocol), transitioning to 2–5 sessions per week for ongoing maintenance. The Kihara long-term outcomes study maintained sessions at least twice weekly after hospital discharge.

Hydration: Weigh before and after each session and replace lost fluid ounce for ounce. Patients on fluid restriction (common in heart failure) should coordinate fluid replacement with their care team.

Clinical supervision: Patients with heart failure, uncontrolled hypertension, unstable angina, or recent myocardial infarction should begin FIR therapy only under physician guidance. The Waon therapy safety profile in the clinical trials was excellent—no serious adverse events across hundreds of patients—but appropriate medical oversight is essential.

Visit Relax Saunas

© 2026 Sol-Ray Biophysics | Relax Sauna | relaxsaunas.com